



Javier Cortes

Contact

Javier Cortes

Publications (5)

Rastogi P, O'Shaughnessy J, Martín M, Boyle F, Cortes J, Rugo H, Goetz M, Hamilton E, Huang C, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andre V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. *J Clin Oncol* 2024;JCO2301994.

Hanna G, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodón J, Ahn M, Kim H, Schneeweiss A, Ribera J, DeAngelo D, Perez Garcia J, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl F, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. *Cancer Res Commun* 2023; 3:1853-1861.

Hamilton E, Chen Y, Zhang W, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer. *Breast Cancer Res Treat* 2022; 195:55-64.

Hamilton E, Johnston E, Bear M, Hardebeck M, Lu Y, Chapman S, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. *Clin Breast Cancer* 2020

Johnston S, Huober J, Wardley A, Tolaney S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol* 2020; 38:3987-3998.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch